The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.

US-based haematologic disease and cancer drug developer Forma Therapeutics priced a $278m initial public offering yesterday that will provide exits for pharmaceutical firms Eli Lilly and Novartis. The offering comprises nearly 13.9 million shares priced at $20 each, above the IPO’s $16 to $18 range and increased from about 11.8 million shares. It will float…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.